Effects of Simvastatin on Uterine Leiomyoma Size

  • End date
    Dec 1, 2024
  • participants needed
  • sponsor
    Johns Hopkins University
Updated on 9 August 2022
pelvic pain
uterine fibroid
uterine bleeding
pap smear
simvastatin 40 mg
uterine myomectomy


The study aims to study the effect of simvastatin on the size of uterine fibroids.


The study is a phase II double blinded clinical trial to determine feasibility, safety and preliminary clinical efficacy of simvastatin to reduce leiomyoma size. Women with symptomatic fibroids planned to undergo surgical management for fibroids such as hysterectomy or myomectomy will be screened for participation. The eligible women will undergo pre-study evaluation to ascertain study eligibility.The study will enroll 60 participants in total, half will receive simvastatin and the other half will receive a placebo. The study drug and placebo will be an add on to the participants ongoing medical management of fibroids until surgery. The participants will be monitored at intervals for the effect of the drug on fibroid size and symptoms using ultrasound and quality of life questionnaires.

Condition Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
Treatment simvastatin 40mg, Placebo 40 mg
Clinical Study IdentifierNCT03400826
SponsorJohns Hopkins University
Last Modified on9 August 2022


Yes No Not Sure

Inclusion Criteria

Signed informed written consent
Gender: female
Age: 18-55 years at time of signing consent
BMI of subjects: < 45 kg/m2
Uterine fibroids
Diagnosed by ultrasound (MRI will be used only if ultrasound is inconclusive)
Number: any number of fibroids
Location: submucosal or intramural
At least one fibroid of diameter > 3cm
Symptoms: one or more of the following symptoms of heavy menstrual bleeding (HMB), defined as: Experienced cyclic (22 to 35 days) abnormal uterine bleeding (heavy or prolonged) in at least 3 of the last 6 menstrual periods, including menstrual bleeding lasting 5 or more days or heavy bleeding per participant recall. Examples of heavy bleeding may include, but are not limited to the following
Requires the use of double protection to manage menstrual bleeding
Menstrual bleeding accompanied by the sensation of "gushing" or "flooding
Saturates more than 1 tampon or sanitary pad per hour for 3 or more consecutive hours
Regularly needs to change the tampon or sanitary pad at night or regularly soils bedclothes
Heavy bleeding that affects work, school, or social activities
Pelvic pain/ pressure likely caused by fibroids
Plan for surgery (hysterectomy or myomectomy)
Normal Pap smear within the last year
Use of contraception during study such as non-hormonal oral contraceptives, intrauterine devices (IUD)/ intrauterine systems (IUS), barrier contraceptives, abstinence or sterilization

Exclusion Criteria

Pregnancy or lactation
Previous or current uterine, cervical or ovarian cancer
Current endometrial hyperplasia or history of atypical endometrial hyperplasia. Endometrial biopsy will be done during screening (if not done within last 12 months)
Suspicion of leiomyosarcoma
Recent rapid growth of fibroids (i.e. doubling in size within 1-6 months period)
Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical dysplasia, or abnormal adnexal/ovarian mass)
Menopausal status
Surgery is urgently indicated (< 3 months) for medical or social reasons
Hemoglobin ≤ 6 g/dL
Currently enrolled in another investigational study
Mental condition or other barrier preventing informed written consent
Allergy or hypersensitivity to simvastatin
Current use of simvastatin or other drugs of the same class
Concomitant administration of strong CYP3A4 inhibitors including itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, and cobicistat-containing products
Concomitant administration of gemfibrozil, cyclosporine, or danazol, verapamil, diltiazem, amiodarone, diltiazem, dronedarone, amlodipine, ranolazine, lomitapide, and grapefruit juice
Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.( elevation of aspartate transaminase and/or alanine transaminase > 2 s.d. above the normal range at screening visit)
Known increased risk or diagnosis of a myopathy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note